Entrepreneurs’ Infrastructure Programme

Doron Ben-Meir
Director, Entrepreneurs’ Infrastructure Programme

13 November, 2014 – NHMRC Symposium on Research Translation
A $484.2 million Programme that provides advice, assistance and tailored support to small and medium businesses to improve business capability and competitiveness, improve collaboration with research institutions, and facilitate the commercialisation of new products, processes and services.

EIP consists of three core elements:

- Business Management
- Research Connections
- Commercialisation
Supporting the commercialisation of novel intellectual property with commercial potential. It will provide access to appropriately skilled, experienced and independent Commercialisation Advisers, facilitate critical business connections through networking opportunities and offer targeted financial assistance.

"The final value proposition for new IP is rarely clear at the outset."
Commercialisation
Piecing it together
Commercialisation
Piecing it together
Commercialisation
Piecing it together
Commercialisation
Piecing it together
Commercialisation
Piecing it together
Value by target market

As at July 2014

- Agriculture and Food
- Automotive, Aviation and Marine
- Business and Communications
- Defence, Security and Safety
- Education and Training
- Energy, Mining and Resources
- Entertainment, Tourism and Sport
- Health and Medical
- Infrastructure and Building
- OEM
- Textiles, Clothing and Footwear

Millions
Global Kinetics Corporation Pty Ltd

- Melbourne based medical technology company
- Developed Parkinson's KinetiGraph (PKG) System, a unique solution for the management of Parkinson's disease symptoms
- PKG records patient symptoms and reports to Clinicians, allowing them to optimize drug performance
- The system also reminds the patient when to take their medication
- $400,000 grant
- Secured US FDA approval – Sep ‘14
Case Study

Admedus (formerly Celxcel Pty Ltd)

- Perth based biotechnology company
- Developed CardioCel®, a regenerative tissue product that treats and repairs congenital heart defects
- $1.9 million grant
- In late 2013 Admedus raised $10.4 million through a rights offer
- In February 2014 the US Federal Drug Administration approved the sale of CardioCel® in the US
Nexvet Biopharma Pty Ltd

- Melbourne based biotechnology company
- Developed a safe and effective therapeutic platform of biological drugs to treat dogs, cats and horses
- $300,000 grant
- Raised $7 million in October 2013
Contact Us

Web: www.Business.gov.au
Phone: 13 28 46